Here are four things to know:
1. The panel voted that Merck Pharmaceuticals, the company that develops sugammadex, has provided sufficient information to characterize the risk for hypersensitivity/anaphylaxis as well as the risk for cardiac dysrhythmias.
2. Sugammadex binds to rocuronium and vecuronium, which induce paralysis during surgery.
3. The FDA has not approved the drug several times due to concerns that include adverse events.
4. The committee’s recommendation is not binding and the FDA is scheduled to make a decision by Dec. 19.
More articles on anesthesia:
ASA names Dr. James Grant first VP: 5 points
Sheridan acquires Valley Anesthesiology & Pain Consultants: 3 things to know
ASA names Dr. Mark Neuman 2015 Presidential Scholar Award: 5 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
